Phase 1/2 Study of Safety/Efficacy Using TRABECTEDIN, IPILIMUMAB and NIVOLUMAB Triple Therapy as First Line Treatment of Advanced Soft Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 20 May 2017 Status changed from active, no longer recruiting to recruiting.
- 05 May 2017 New trial record
- 04 May 2017 Planned End Date changed from 20 May 2020 to 31 Aug 2020.